Baijin Life Science Holdings Limited (HKG:1466)
Hong Kong · Delayed Price · Currency is HKD 1.250
+0.075 (6.38%)
At close: Sep 9, 2026
HKG:1466 Ratios and Metrics
Market cap in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,165 | 550 | 488 | 442 | 454 | 39 | |
Market Cap Growth | 211.08% | 12.75% | 10.50% | -2.73% | 1063.93% | 17.12% |
Enterprise Value | 1,157 | 594 | 529 | 403 | 441 | 44 |
Last Close Price | 1.25 | 0.59 | 0.69 | 0.65 | 0.71 | 0.12 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | - | - | 52.32 | - |
PS Ratio | 13.05 | 6.16 | 3.60 | 8.23 | 5.22 | 0.62 |
PB Ratio | 6.06 | 2.86 | 3.13 | 3.91 | 5.80 | 1.09 |
P/TBV Ratio | 7.05 | 3.33 | 4.65 | 10.88 | 5.80 | 1.09 |
P/FCF Ratio | - | - | - | - | - | 36.69 |
P/OCF Ratio | - | - | - | - | - | 35.16 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 12.95 | 6.66 | 3.91 | 7.51 | 5.08 | 0.70 |
EV/EBITDA Ratio | - | - | 29.90 | - | - | - |
EV/EBIT Ratio | - | - | 37.69 | - | - | - |
EV/FCF Ratio | - | - | - | - | - | 41.09 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.15 | 0.15 | 0.64 | 0.45 | 0.04 | 0.89 |
Debt / EBITDA Ratio | - | - | 4.83 | - | - | 28.25 |
Debt / FCF Ratio | - | - | - | - | - | 29.95 |
Net Debt / Equity Ratio | -0.08 | -0.08 | 0.33 | 0.11 | -0.50 | 0.21 |
Net Debt / EBITDA Ratio | 0.64 | 0.64 | 2.90 | -1.41 | 15.75 | -196.54 |
Net Debt / FCF Ratio | 0.69 | 0.69 | -1.56 | -1.90 | 1.81 | 7.21 |
Asset Turnover | 0.32 | 0.32 | 0.56 | 0.36 | 0.96 | 0.72 |
Inventory Turnover | 1.28 | 1.28 | 1.63 | 0.80 | 2.31 | 2.12 |
Quick Ratio | 1.61 | 1.61 | 2.93 | 1.68 | 2.34 | 1.12 |
Current Ratio | 2.97 | 2.97 | 4.57 | 2.96 | 4.69 | 1.75 |
Return on Equity (ROE) | -24.52% | -24.52% | -0.07% | -8.94% | 15.20% | -37.80% |
Return on Assets (ROA) | -6.74% | -6.74% | 3.60% | -4.04% | -1.84% | -0.16% |
Return on Capital Employed (ROCE) | -15.00% | -15.00% | 5.80% | -6.10% | -3.40% | -0.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -3.25% | -6.88% | -0.07% | -1.69% | 1.91% | -39.65% |
FCF Yield | -1.95% | -4.13% | -6.76% | -1.50% | -4.75% | 2.73% |
Buyback Yield / Dilution | -30.54% | -30.54% | -7.58% | -6.89% | -70.17% | -58.07% |